Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence
September 26 2024 - 8:30AM
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage
biotechnology company pioneering the development of allogeneic CAR
T (AlloCAR T™) products for cancer and autoimmune disease, today
announced that it will present pre-clinical data for its
next-generation investigational AlloCAR T candidate for autoimmune
indications, ALLO-329, at the American College of Rheumatology's
annual meeting, ACR Convergence 2024, being held from November
14-19 in Washington, D.C.
ALLO-329, the Company’s CD19/CD70 dual AlloCAR T product is the
first CAR T designed to both reduce or eliminate the need for
lymphodepletion while also targeting CD19+ B-cells and CD70+
activated T-cells, both of which are likely to play a role in
autoimmune diseases. ALLO-329 utilizes CRISPR-based site-specific
integration for dual CAR expression.
“We are at the beginning of understanding what may be possible
for CAR T in autoimmune disease. However, the only way to fully
realize the potential of the modality is to develop product
candidates designed to meet the specific needs of this vast patient
population and allow for greater implementation in real-world
practice. This is how we have designed ALLO-329,” said Zachary
Roberts, M.D., Ph.D., Executive Vice President of Research &
Development of Allogene. “We believe the first and most important
factor for the potential success of CAR T in autoimmune disease is
being available off-the-shelf to meet potential demand. Next, we
have addressed lymphodepletion by incorporating our proprietary and
clinically validated Dagger® technology, which is designed to
enable cells to expand and persist in patients without or with
potentially reduced chemotherapy conditioning. Lastly, our dual CAR
targets both the B- and T-cell components of autoimmune disease,
which we believe may allow for a broader application of CAR T
across a multitude of indications.”
Allogene Abstract: Title: Preclinical Evaluation of ALLO-329:
Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR
for the Treatment of Autoimmune DiseasesPresenter: Kristen Zhang,
Research Scientist, Allogene TherapeuticsAbstract Number:
1841Poster Session: T Cell Biology & Targets in Autoimmune
& Inflammatory Disease PosterDate and Time: Monday, November
18, 10:30 a.m-12:30 p.m. ET
The abstract can be found on the American College of
Rheumatology’s website.
The Company plans to file an investigational new drug (IND)
application with the U.S. Food and Drug Administration in the first
quarter of 2025 and expects to have proof-of-concept by year-end
2025.
About Allogene TherapeuticsAllogene
Therapeutics, with headquarters in South San Francisco, is a
clinical-stage biotechnology company pioneering the
development of allogeneic chimeric antigen receptor T cell
(AlloCAR T™) products for cancer and autoimmune disease. Led by a
management team with significant experience in cell therapy,
Allogene is developing a pipeline of “off-the-shelf” CAR T cell
product candidates with the goal of delivering readily
available cell therapy on-demand, more reliably, and
at greater scale to more patients. For more information,
please visit www.allogene.com, and follow Allogene
Therapeutics on X (formerly Twitter) and LinkedIn.
Cautionary Note on Forward-Looking Statements for
AllogeneThis press release contains forward-looking
statements for purposes of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. The press release
may, in some cases, use terms such as “predicts,” “projects,”
“believes,” “potential,” “proposed,” “advance,” “making,”
“continue,” “likely,” “designed to,” “estimates,” “anticipates,”
“expects,” “envision,” “plans,” “intends,” “look to,” “may,”
“could,” “might,” “will,” “should” or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things:
the timing of filing Investigational New Drug applications,
achieving proof-of-concept relating to autoimmune disease, and the
progress and success of such clinical program; the ability to
reduce or eliminate lymphodepletion in autoimmune disease; the
potential for our dual CAR targeting B- and T-cell components of
autoimmune disease will allow for broader application of CAR T
across a multitude of indications; the potential for our product
candidates to be approved; the potential benefits of AlloCAR T
products; the ability of our product candidates to treat autoimmune
disease; our ability to meet the specific needs of the patient
population and allow for greater implementation; the extent to
which our clinical trials will support regulatory approval of our
product candidates; our ability to deliver cell therapy on-demand,
more reliably, and at greater scale to more patients. Various
factors may cause material differences between Allogene’s
expectations and actual results, including, risks and uncertainties
related to: the extent to which Dagger-endowed cells expand and
persist in patients with less reliance on chemotherapy
conditioning; our product candidates are based on novel
technologies, which makes it difficult to predict the time and cost
of product candidate development and obtaining regulatory approval;
our product candidates may cause undesirable side effects or have
other properties that could halt their clinical development,
prevent their regulatory approval or limit their commercial
potential; the extent to which the Food and Drug Administration
disagrees with our clinical or regulatory plans or the import of
our clinical results, which could cause future delays to our
clinical trials, including initiation of clinical trials, or
require additional clinical trials; we may encounter difficulties
enrolling patients in our clinical trials; we may not be able to
demonstrate the safety and efficacy of our product candidates in
our clinical trials, which could prevent or delay regulatory
approval and commercialization; and challenges with manufacturing
or optimizing manufacturing of our product candidates. These and
other risks are discussed in greater detail in Allogene’s filings
with the SEC, including without limitation under the “Risk Factors”
heading in its Quarterly Report on Form 10-Q for the quarter ended
June 30, 2024. Any forward-looking statements that are made in this
press release speak only as of the date of this press release.
Allogene assumes no obligation to update the forward-looking
statements whether as a result of new information, future events or
otherwise, after the date of this press release.
AlloCAR T™ and Dagger® are trademarks of Allogene
Therapeutics, Inc.
Allogene Media/Investor Contact:Christine
CassianoEVP, Chief Corporate Affairs & Brand Strategy
OfficerChristine.Cassiano@allogene.com
Additional Allogene Media Contacts:Leslie
BryantLeslie.Bryant@allogene.com
Madeleine GoldsteinMadeleine.Goldstein@allogene.com
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From Sep 2023 to Sep 2024